NEO Trial Investigates Tissue-Free ctDNA in Early-Stage Rectal Cancer
Audio narration · Coming soon
The NEO trial focuses on the use of tissue-free circulating tumor DNA (ctDNA) in early-stage rectal cancer. This research aims to advance cancer care and treatment by exploring non-invasive methods for detecting and monitoring cancer.
Why this matters
PRISM scored this story 55/100 for interest.
Originally published by gnews